Showing results (131-140 of 777) with videos related to

Sort By:
Pageof 78
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
Expert Review of Anticancer Therapy|July 1, 2008
Bortezomib in the front-line treatment of multiple myelomaPaul G Richardson, Constantine Mitsiades, Robert Schlossman, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 23, 2002
Molecular sequelae of proteasome inhibition in human multiple myeloma cellsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Leukemia|August 30, 2019
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
British Journal of Haematology|September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Cancer Research|October 3, 2003
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
British Journal of Haematology|February 21, 2006
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myelomaShaji Kumar, Noopur Raje, Teru Hideshima, et al.
Blood|May 5, 2005
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Pageof 78